You are here:
Home / Archives for ENZN
On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009. Nonetheless, at the start of the year we [...]
Filed under Articles · Tagged with Amgen, AMGN, AMLN, Amylin Pharmaceuticals, BIIB, Biogen Idec, biotechnology, BTK, CELG, Celgene, Dendreon, DNDN, ENZN, Enzon Pharmaceuticals, GENZ, Genzyme General, GILD, Gilead Sciences, GTx Inc, GTXI, HGSI, Human Genome Sciences, Impax Laboratories, IPXL, life sciences, NASDAQ Biotech Index, NBI, NPS Pharmaceuticals, NPSP, NYSE Arca Biotechnology Index, OGXI, Oncogenex Pharmaceuticals, OSIR, Osiris Therapeutics, PGNX, Progenics Pharmaceuticals, Salix Pharmaceuticals, Santarus, SLXP, SNGX, SNTS, Soligenix, Vanda Pharmaceuticals, VNDA
Although a controversial topic, activist hedge funds and private equity firms typically use a small equity stake in an underperforming company to put public pressure on its management and board of directors with the goal of increasing stakeholder value through cost cutting, changes in corporate strategy or management, capital restructuring, asset divestiture and other tactics. [...]
Filed under Articles · Tagged with Abelcet, activism, activist, Adagen, Alexander Denner, Alkermes, ALKS, AMLN, Amylin Pharmaceuticals, AstraZeneca plc, Avonex, AZN, BIIB, Biogen Idec, biotech, biotechnology, Biotechnology Value Fund, BMY, Bristol-Myers Squibb, Byetta, canfosfamide, Carl Icahn, cetuximab, DellaCamera Capital Management, DepoCyt, Eastbourne Capital Management, Eli Lilly, Eli Lilly & Co, EMIS, Emisphere Technologies, Endo Pharmaceuticals, ENDP, ENZN, Enzon Pharmaceuticals, Erbitux, EXEL, Exelixis, exenatide, Icahn Management, ImClone, interferon beta-1a, interferon beta-1b, LLY, Medarex, MedImmune, medx, multiple sclerosis, NASDAQ Biotechnology Index, NBI, Novartis AG, NVS, Oncaspar, Regeneron Pharmaceuticals, REGN, Richard Mulligan, shareholder activist, Telcyta, Telik, TELK, Third Point LLC
